结核分枝杆菌耐利奈唑胺相关基因研究进展  

Progress on Drug Resistance Related Genes of Mycobacterium Tuberculosis to Linezolid

作　　者：唐正洪 陈玲[1] TANG Zheng-hong;CHEN Ling(The Second Department of Respiratory Medicine,the Affiliated Hospital of Zunyi Medical College,Zunyi 563003,China)

机构地区：[1]遵义医学院附属医院呼吸二科,贵州省遵义市563003

出　　处：《实用心脑肺血管病杂志》2018年第11期28-31,共4页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

基　　金：国家自然科学基金资助项目(81760003)

摘　　要：耐多药结核病(MDR-TB)及耐利福平结核病(RR-TB)均需采用二线抗结核药物治疗。利奈唑胺属恶唑烷酮类抗生素,是治疗MDR-TB及RR-TB的二线核心抗结核药物之一,其抗结核作用较强,但近年来结核分枝杆菌对利奈唑胺耐药现象增多且具体耐药机制尚未完全明确。本文综述了结核分枝杆菌耐利奈唑胺相关基因,旨在为结核分枝杆菌对利奈唑胺的耐药机制研究提供参考。Second-line anti-tuberculosis drugs are needed in treating MDR-TB and rifampicin-resistant tuberculosis(RR-TB). Linezolid is one of antibiotics belongs to oxazolidinones,and as one of core second-line anti-tuberculosis drugs in treating MDR-TB and RR-TB,has fairly strong anti-tuberculosis effect,but drug resistance of Mycobacterium tuberculosis to linezolid gradually increased,and the resistance mechanism is not completely clear. This paper reviewed the drug resistance related genes of Mycobacterium tuberculosis to linezolid,to provide a reference for the research on resistance mechanisms of Mycobacterium tuberculosis to linezolid.

关 键 词：结核分枝杆菌 结核 抗多种药物性 广泛耐药结核 利奈唑胺 基因 突变 综述 

分 类 号：R378.911[医药卫生—病原生物学] R394.2[医药卫生—基础医学]